Fig. 6.
Fig. 6. B7-dependent rejection of J558 tumor: role of CD28 and CTLA4. / (A) Diagram of experimental design. J558-B7 and J558 tumor cells were injected at separate flanks of the RAG-2−/− BALB/c mice. These mice then either received no T cells or they received CD28+/− or CD28−/− T cells on the day of tumor injection. The tumor incidence (top panels) and growth kinetics were monitored. (B) Tumor rejection by 5 × 106 of CD28+/− or CD28−/− P1CTL. Groups that received no T cells or CD28+/− T cells had 3 mice per group; the group that received CD28−/− T cells consisted of 5 mice. The sizes of J558-Neo and J558-B7 tumors in mice that received CD28−/− P1CTL were significantly different between day 12 and day 22 (2-sided P value between .05 and .0001 by Student t test).

B7-dependent rejection of J558 tumor: role of CD28 and CTLA4.

(A) Diagram of experimental design. J558-B7 and J558 tumor cells were injected at separate flanks of the RAG-2−/− BALB/c mice. These mice then either received no T cells or they received CD28+/− or CD28−/− T cells on the day of tumor injection. The tumor incidence (top panels) and growth kinetics were monitored. (B) Tumor rejection by 5 × 106 of CD28+/− or CD28−/− P1CTL. Groups that received no T cells or CD28+/− T cells had 3 mice per group; the group that received CD28−/− T cells consisted of 5 mice. The sizes of J558-Neo and J558-B7 tumors in mice that received CD28−/− P1CTL were significantly different between day 12 and day 22 (2-sided P value between .05 and .0001 by Student t test).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal